Quick Answer
Ensysce Biosciences, Inc. reported Net Income Loss of $2.40 million for the year ending 2020.
- Ensysce Biosciences, Inc. showed an increase of +557.1% in Net Income Loss from 2019 to 2020.
- This data is from Ensysce Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 15, 2021.
- XBRL data for this metric is available from 2018 to 2020 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: -$5.0 thousand | Q4 2017: -$31.2 thousand | Q1 2018: $406.1 thousand | Q2 2018: $415.1 thousand | Q3 2018: $577.6 thousand | Q1 2019: $775.9 thousand | Q2 2019: $418.9 thousand | Q3 2019: $489.7 thousand | Q1 2020: $1.79 million | Q2 2020: -$704.5 thousand | Q3 2020: $1.57 million | Q1 2021: -$1.71 million | Q2 2021: -$935.5 thousand | Q3 2021: -$17.16 million.
- Over the full 3 years of available data (2018 to 2020), Ensysce Biosciences, Inc.'s Net Income Loss has grown by 13.3%.
- Historical annual values: Fiscal year 2020: $2.40 million | Fiscal year 2019: $366.0 thousand | Fiscal year 2018: $2.12 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: